After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. See why NVO stock is a Buy.

Novo Nordisk has launched its weight-loss drug Wegovy in China — but for a tiny fraction of what it's charging customers in ...

Ozempic and Mounjaro were among the medicines The i Paper found promoted for sale in weight loss groups on the social media ...